drugset / Trial / NCT06035354
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of AK120 in Subjects With Atopic Dermatitis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a randomized, double-blind, placebo-controlled, multicenter phase Ib/II clinical study to evaluate the safety, pharmacokinetics and efficacy of AK120 in the treatment of subjects with moderate to severe atopic dermatitis.
Timeline
- Start
- 2021-11-03
- Primary completion
- 2024-06-21
- Completion
- 2024-06-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AK120 | Monoclonal antibody | 150 mg | Subcutaneous |
| Subject | AK120 | Monoclonal antibody | 300 mg | Subcutaneous |
| Subject | AK120 | Monoclonal antibody | 450 mg | Subcutaneous |